Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$17.65
-$2.34(-11.71%)
At close: 4:00 PM EDT
$17.65
-$2.34(-11.71%)
Day’s Range― - ―
52-Week Range$9.82 - $21.45
Previous CloseN/A
Volume3.88M
Average Volume (3M)1.89M
Market Cap
$2.01B
Enterprise Value$1.54K
Total Cash (Recent Filing)$440.56M
Total Debt (Recent Filing)$233.42M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Oct 22, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding116,445,840
10 Day Avg. Volume2,096,710
30 Day Avg. Volume1,887,454
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.50Price Target Upside67.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$725.79M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue And Patient GrowthRevenue and active-patient growth indicate expanding adoption of the recurring-use TTFields platform. Continued utilization growth can support durable commercial scale across existing indications and improve operating leverage.
Strong Gross Margin And Cost DisciplineA high gross-margin profile, lower array costs and disciplined operating expenses provide a foundation for improving profitability. These efficiencies may persist as manufacturing utilization improves and the commercial platform scales.
Product Expansion And Regulatory ProgressRegulatory clearance expands NovoCure's addressable market beyond its established indications and supports a broader oncology platform. Positive survival and quality-of-life results may strengthen physician and payer adoption over time.
Bears Say
Persistent Losses And Negative Free Cash FlowDespite revenue growth and improved adjusted EBITDA, NovoCure remains GAAP loss-making and cash-flow negative. Sustained investment in launches and trials could continue consuming cash and limit financial flexibility if profitability is delayed.
Reimbursement And Adoption BarriersGrowth depends on converting initial prescriptions into sustained treatment and overcoming market-access friction. Contracting requirements and limited repeat prescribing could slow patient additions, revenue visibility and the return on launch investment.
Clinical Execution And Evidence RiskClinical setbacks or redesigned studies can weaken evidence supporting broader TTFields adoption and delay future indications. Reduced enrollment or altered protocols may also increase uncertainty around regulatory outcomes and commercialization timing.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $21.45 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $2.01B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 63 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Jul 23, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.202.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.25.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 116,445,840 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went up 28.388%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.50 (67.14% Upside)
$29.50 (67.14% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Company Deck
NVCR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum highlighted by record net revenue (+16% YoY), active patient growth (Optune Gio +11% YoY), successful early launches (Optune Pax and Optune Lua), and a return to positive adjusted EBITDA in the quarter. Management also emphasized disciplined cost-management actions (R&D reductions and LUNAR-2 optimization) and updated full-year guidance reflecting confidence in continued progress. Key challenges include reimbursement and contracting hurdles (EU and Japan), reliance on some one-time benefits in Q2, the need to convert one-time prescribers into repeat prescribers for sustained growth, and clinical trial redesign risks. Overall, the positives — stronger commercial performance, profitability trajectory, regulatory milestones and clear launch progress — meaningfully outweigh the identified lowlights.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$29.50
▲(67.14% Upside)
Technical Analysis
Ownership Overview
2.72% Insiders
22.46% Mutual Funds
17.06% Other Institutional Investors
41.05% Public Companies and
Individual Investors